558 related articles for article (PubMed ID: 17496434)
21. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
22. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
23. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
24. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
Lebovitz HE
Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
Downie MM; Sanders DA; Maier LM; Stock DM; Kealey T
Br J Dermatol; 2004 Oct; 151(4):766-75. PubMed ID: 15491415
[TBL] [Abstract][Full Text] [Related]
26. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
27. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
[TBL] [Abstract][Full Text] [Related]
28. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
Rosenson RS
Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
[TBL] [Abstract][Full Text] [Related]
29. Selective PPAR agonists for the treatment of type 2 diabetes.
Nehlin JO; Mogensen JP; Petterson I; Jeppesen L; Fleckner J; Wulff EM; Sauerberg P
Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025
[TBL] [Abstract][Full Text] [Related]
30. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
31. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
32. PPAR and Pain.
Maeda T; Kishioka S
Int Rev Neurobiol; 2009; 85():165-77. PubMed ID: 19607969
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular disease and PPARdelta: targeting the risk factors.
Muscat GE; Dressel U
Curr Opin Investig Drugs; 2005 Sep; 6(9):887-94. PubMed ID: 16187688
[TBL] [Abstract][Full Text] [Related]
34. Strategies for the development of new PPAR agonists in diabetes.
Cavender MA; Nicholls SJ; Lincoff AM
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
[TBL] [Abstract][Full Text] [Related]
35. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
37. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
38. [PPARs and heart diseases].
Takano H; Komuro I
Nihon Rinsho; 2005 Apr; 63(4):659-64. PubMed ID: 15828234
[TBL] [Abstract][Full Text] [Related]
39. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
40. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
